Obagi Medical and Moxie Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
On February 5, 2026, Obagi Medical announced a strategic collaboration with Moxie to enhance the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Obagi Medical, recognized for its innovative physician-dispensed skincare solutions and part of Waldencast plc, is joining forces with Moxie, a company known for providing comprehensive software, marketing, coaching, and compliance solutions tailored for med spa entrepreneurs. This partnership aims to generate meaningful real-world evidence concerning Obagi’s new injectable, the saypha® MagIQ™, across Moxie's network of aesthetic practices.
Through this collaborative effort, Moxie will spearhead a systematic evaluation of the saypha® MagIQ™ filler, utilizing its expertise in operational tools and data-driven insights to assess its integration within aesthetic workflows. Moxie CEO Kamau Massey emphasized the synergy between their mission of empowering aesthetic entrepreneurs with the ALOHA Program, which focuses on innovation and improving patient outcomes.
The ALOHA Program aims to comprehensively evaluate both clinical performance and patient experience while providing integrated protocols to enhance satisfaction and loyalty among patients. Standardized data will be collected from Moxie-supported practices, with insights expected to be presented at industry events. Drew Fine, U.S. General Manager for the Professional Channel at Obagi, highlighted how the partnership aligns with their commitment to enabling practices of various sizes to thrive through modern solutions.
Obagi’s saypha® MagIQ™, leveraging leading MACRO Core Technology, promises high usability and predictable results, reinforcing their ethos of providing effective skincare solutions. The collaboration with Moxie reaffirms Obagi's dedication to advancing the aesthetics field, ensuring practitioners can offer top-notch care in a competitive market. For additional insights on the ALOHA Program, further details can be found on Obagi's official website.
MWN-AI** Analysis
Obagi Medical's recent collaboration with Moxie to launch the ALOHA Program positions it to gain significant traction in the med spa market. This strategic partnership highlights Obagi's commitment to integrating innovative technologies with clinical practices, ultimately driving real-world evidence for its flagship product, the Obagi® saypha® MagIQ™ injectable.
For investors, this collaboration represents a compelling opportunity. Moxie's expertise in streamlining operations for aesthetic practices, combined with Obagi’s proven skincare solutions, creates a robust framework for establishing market share and driving customer loyalty. By generating standardized clinical data across multiple practices, the ALOHA Program aims to validate the efficacy and patient satisfaction associated with Obagi's offerings. This data-driven approach can result in improved marketing and sales strategies, thereby boosting revenue and enhancing investor confidence.
Furthermore, the focus on various practice sizes means Obagi can penetrate a wider range of service providers, from small independent clinics to large chains. This inclusivity can amplify adoption rates across diverse market segments, reinforcing Obagi's Aesthetics for All™ mantra. The timing is pivotal, as medspa demand continues to grow due to social media influence and increased consumer focus on aesthetic treatments.
Investors should monitor initial findings from the ALOHA Program presented at industry conferences. Positive results could significantly elevate Obagi’s market position, bolstering sales of the saypha® MagIQ™ product line and promoting new customer acquisition. Additionally, as Waldencast plc continues to grow, backed by its ambitions to build a best-in-class beauty ecosystem, investors can expect further strategic moves that may enhance shareholder value.
In summary, the Obagi-Moxie collaboration is a promising indicator of revenue growth and market expansion, making it a noteworthy consideration for investors looking at the evolving aesthetic medicine landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Moxie as a strategic partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Moxie was selected for its expertise in providing all-in-one software, marketing, coaching, and compliance solutions that help med spa entrepreneurs launch, scale, and optimize their practices with predictable growth, profitability, and a foundation of clinical and operational excellence.
Through this real-world evaluation collaboration, Moxie will facilitate a structured assessment of Obagi® saypha® MagIQ™ across its network of supported aesthetic practices. The program will leverage Moxie’s strengths in data-driven insights, operational tools, and expert coaching to generate meaningful real-world evidence on the filler’s integration into scalable aesthetic workflows.
“At Moxie, we’re dedicated to empowering aesthetic practice entrepreneurs with the tools, support, and strategies needed to build thriving, compliant practices,” said Kamau Massey, CEO of Moxie. “Obagi’s ALOHA Program resonates with our focus on innovation and real-world results, allowing us to help our partners incorporate advanced injectables like saypha® MagIQ™ alongside comprehensive skincare protocols to enhance patient outcomes and business success.”
The ALOHA Program evaluates both clinical performance and patient experience while equipping providers with integrated Obagi protocols to drive satisfaction, loyalty, and consistent results. Standardized data will be collected across participating Moxie-supported practices, with initial findings to be shared at upcoming Moxie events and presented at key industry conferences to demonstrate the impact of this new injectable in technology-enabled med spa environments.
“The Moxie opportunity is unique and highlights Obagi’s Aesthetics for All™ ethos with a focus on supporting practices of all sizes and shapes," said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA partnership with Moxie combines cutting-edge software and coaching with our skincare and injectables expertise in addition to targeted marketing efforts to empower practices and elevate patient care in a rapidly evolving market.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About Moxie
Moxie is the clinical-grade operating system built exclusively for aesthetic medicine, helping ambitious practice owners scale without compromise. From charting and compliance to marketing, finance, and coaching, Moxie brings every operational need under one roof—so practices can grow safely, sustainably, and with integrity. Learn more at joinmoxie.com
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does Waldencast Acquisition Corp. WALD plan to leverage the Moxie partnership to enhance its position in the competitive aesthetics market, particularly through the ALOHA Program?
In what ways does the integration of Obagi’s Hyaluronic Acid (ALOHA) Program with Moxie improve the business scalability for med spa entrepreneurs associated with Waldencast Acquisition Corp. WALD?
What are the expected outcomes of the real-world evaluation of Obagi’s saypha® MagIQ™ as part of the ALOHA Program, and how does Waldencast Acquisition Corp. WALD anticipate this data will influence investor interest?
How does Waldencast Acquisition Corp. WALD ensure compliance and operational excellence within the aesthetic practices supported by Moxie, particularly regarding the deployment of advanced injectables?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
3.9% G/L:
$1.60 Last:
8,798 Volume:
$1.56 Open:
